ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2014
Overview of a chemoresponse assay in ovarian cancer.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer.Journal of translational medicine · 2016Trial
- Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer.NPJ precision oncology · 2024Article
- Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs.Human cell · 2023Article
- Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.Clinical epigenetics · 2021Article
- Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.HSOA journal of stem cells research, development & therapy · 2021Article
- Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer.Translational oncology · 2020Article
- Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.Scientific reports · 2019Article
- Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model.Cancers · 2019Article
- Targeting minimal residual disease: a path to cure?Nature reviews. Cancer · 2018Review
- Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.Theranostics · 2018Review
- The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.Scientific reports · 2017Article
- NewPeerJ · 2017Article
- Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.Current pharmaceutical design · 2016Review
- Precision medicine for cancer with next-generation functional diagnostics.Nature reviews. Cancer · 2015Review
- Use of ChemoFx® for Identification of Effective Treatments in Epithelial Ovarian Cancer.PLoS currents · 2015Article
- Evaluation of chemoresponse assays as predictive markers.British journal of cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this review is to summarize recent scientific and medical literature regarding chemoresponse assays or chemotherapy sensitivity and resistance assays (CSRAs), specifically as applied to epithelial ovarian cancer. A total of sixty-seven articles, identified through PubMed using the key words "in vitro chemoresponse assay," "chemo sensitivity resistance assay," "ATP," "HDRA," "EDR," "MiCK," and "ChemoFx," were reviewed. Recent publications on marker validation, including relevant clinical trial designs, were also included. Recent CSRA research and clinical studies are outlined in this review. Published findings demonstrate benefits regarding patient outcome with respect to recent CSRAs. Specifically, analytical and clinical validations, as well as clinical utility and economic benefit, of the most common clinically used CSRA in the United States support its use to aid in making effective, individualized clinical treatment selections for patients with ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.